Influence of H. pylori infection and eradication on p53, c-erbB-2 and Ki-67 in gastric mucosa.
OBJECTIVE
To evaluate the expression of antigens c-erbB-2, p53, and Ki-67 in gastric biopsy, bacteria density and urease activity in two groups of patients with chronic gastritis separated on the basis of the success or failure of H. pylori eradication.


METHODS
Sixty-five patients with chronic gastritis were split in two groups (n=45/20) related to response to the therapy. The gastric mucosa samples (Sydney system) were analyzed histologically in both groups of patients before and after standard therapy (for eradicated, E group after one cycle; for non-eradicated, NE group after three cycles) for H. pylori infection, urease activity, c-erbB-2, p53 and Ki-67 expression. Sera samples taken before and after treatment were also analyzed for specific antibody against H. pylori.


RESULTS
The eradication of H. pylori in patients of the E group was accompanied with significant lower colonization grades of bacteria, urease activity, proliferating rate, p53, and Ki-67 expression while c-erbB-2 expression was unchanged. In the NE group, all parameters were the same before and after therapy with exception of p53, which was slightly higher on both locations. Strong expression of c-erbB-2 in corpus of the NE group was determinate. Serum activity of specific antibodies against H. pylori was lower after the therapy in both groups of patients, but in the eradicated group this change was much stronger that in the non-eradicated.


CONCLUSIONS
Long persisting infection is related with higher colonization grades of bacteria, urease activity, p53, c-erbB-2 and Ki-67 expression. Changes of those markers are connected with duration of infection and location where these changes were obtained.
Brajsa
Karmen
K
Research Institute PLIVA, Department of Pharmacology and Medicinal Safety, Zagreb, Croatia.
Ferencic
Zeljko
Z
Katicic
Miroslava
M
Radosevic
Senka
S
Presecki
Vladimir
V
Spaventi
Radan
R
Dominis
Marja
M
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001426:Bacterial Proteins / Q000032:analysis; D049109:Cell Proliferation; D002908:Chronic Disease; D005260:Female; D005753:Gastric Mucosa / Q000737:chemistry / Q000378:metabolism / Q000382:microbiology; D005756:Gastritis / Q000188:drug therapy / Q000378:metabolism* / Q000382:microbiology*; D016481:Helicobacter Infections / Q000188:drug therapy / Q000378:metabolism*; D016480:Helicobacter pylori / Q000201:enzymology / Q000302:isolation & purification; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000032:analysis / Q000378:metabolism*; D015854:Up-Regulation; D014510:Urease / Q000032:analysis
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D016159:Tumor Suppressor Protein p53; D014510:Urease